vs
Side-by-side financial comparison of Farmland Partners Inc. (FPI) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Farmland Partners Inc. is the larger business by last-quarter revenue ($20.7M vs $18.6M, roughly 1.1× SCYNEXIS INC). Farmland Partners Inc. runs the higher net margin — 103.4% vs 65.7%, a 37.7% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -3.5%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 31.4%).
Farmland Industries was the largest agricultural cooperative in North America when it eventually sold all of its assets in 2002–04. During its 74-year history, Farmland served its farmer membership as a diversified, integrated organization, playing a significant role in agricultural markets both domestically and worldwide.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
FPI vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.7M | $18.6M |
| Net Profit | $21.4M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | — | 56.3% |
| Net Margin | 103.4% | 65.7% |
| Revenue YoY | -3.5% | 1808.5% |
| Net Profit YoY | -63.5% | 376.5% |
| EPS (diluted) | $0.44 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.7M | $18.6M | ||
| Q3 25 | $11.3M | $334.0K | ||
| Q2 25 | $10.0M | $1.4M | ||
| Q1 25 | $10.3M | $257.0K | ||
| Q4 24 | $21.5M | $977.0K | ||
| Q3 24 | $13.3M | $660.0K | ||
| Q2 24 | $11.4M | $736.0K | ||
| Q1 24 | $12.0M | $1.4M |
| Q4 25 | $21.4M | $12.3M | ||
| Q3 25 | $483.0K | $-8.6M | ||
| Q2 25 | $7.6M | $-6.9M | ||
| Q1 25 | $2.0M | $-5.4M | ||
| Q4 24 | $58.7M | — | ||
| Q3 24 | $1.8M | $-2.8M | ||
| Q2 24 | $-2.0M | $-14.5M | ||
| Q1 24 | $1.4M | $411.0K |
| Q4 25 | — | 56.3% | ||
| Q3 25 | 4.3% | -2516.5% | ||
| Q2 25 | 78.2% | -701.0% | ||
| Q1 25 | 20.6% | -3350.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | 13.9% | -1563.6% | ||
| Q2 24 | -17.9% | -1255.0% | ||
| Q1 24 | 11.9% | -692.5% |
| Q4 25 | 103.4% | 65.7% | ||
| Q3 25 | 4.3% | -2572.2% | ||
| Q2 25 | 76.3% | -504.8% | ||
| Q1 25 | 19.9% | -2097.7% | ||
| Q4 24 | 273.6% | — | ||
| Q3 24 | 13.5% | -425.5% | ||
| Q2 24 | -17.5% | -1964.4% | ||
| Q1 24 | 11.5% | 29.9% |
| Q4 25 | $0.44 | $0.25 | ||
| Q3 25 | $0.00 | $-0.17 | ||
| Q2 25 | $0.14 | $-0.14 | ||
| Q1 25 | $0.03 | $-0.11 | ||
| Q4 24 | $1.09 | — | ||
| Q3 24 | $0.02 | $-0.06 | ||
| Q2 24 | $-0.06 | $-0.30 | ||
| Q1 24 | $0.01 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $40.0M |
| Total DebtLower is stronger | $161.6M | — |
| Stockholders' EquityBook value | $467.4M | $49.4M |
| Total Assets | $719.1M | $59.0M |
| Debt / EquityLower = less leverage | 0.35× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $37.9M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $68.8M | ||
| Q2 24 | — | $73.0M | ||
| Q1 24 | — | $80.2M |
| Q4 25 | $161.6M | — | ||
| Q3 25 | $170.4M | — | ||
| Q2 25 | $193.4M | — | ||
| Q1 25 | $202.6M | — | ||
| Q4 24 | $204.6M | — | ||
| Q3 24 | $394.0M | — | ||
| Q2 24 | $393.0M | — | ||
| Q1 24 | $383.0M | — |
| Q4 25 | $467.4M | $49.4M | ||
| Q3 25 | $457.3M | $36.4M | ||
| Q2 25 | $473.5M | $44.5M | ||
| Q1 25 | $492.2M | $50.5M | ||
| Q4 24 | $494.6M | $55.1M | ||
| Q3 24 | $519.4M | $58.5M | ||
| Q2 24 | $521.5M | $60.4M | ||
| Q1 24 | $526.7M | $74.1M |
| Q4 25 | $719.1M | $59.0M | ||
| Q3 25 | $738.5M | $51.1M | ||
| Q2 25 | $776.7M | $60.7M | ||
| Q1 25 | $810.5M | $67.9M | ||
| Q4 24 | $869.6M | $90.6M | ||
| Q3 24 | $1.0B | $99.0M | ||
| Q2 24 | $1.0B | $107.8M | ||
| Q1 24 | $1.0B | $118.3M |
| Q4 25 | 0.35× | — | ||
| Q3 25 | 0.37× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.41× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 0.73× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.4M | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.81× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.4M | $18.4M | ||
| Q3 25 | $-2.0M | $-8.7M | ||
| Q2 25 | $-2.2M | $-7.5M | ||
| Q1 25 | $6.4M | $-7.5M | ||
| Q4 24 | $16.1M | $-24.0M | ||
| Q3 24 | $-4.3M | $765.0K | ||
| Q2 24 | $-6.1M | $-10.9M | ||
| Q1 24 | $11.9M | $-4.0M |
| Q4 25 | 0.81× | 1.50× | ||
| Q3 25 | -4.04× | — | ||
| Q2 25 | -0.29× | — | ||
| Q1 25 | 3.12× | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | -2.39× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 8.66× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FPI
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
